|1.||Patel, Pankaj A: 4 articles (07/2009 - 04/2006)|
|2.||Mody, Reema R: 3 articles (07/2009 - 03/2008)|
|3.||Wu, Eric Q: 2 articles (08/2015 - 03/2008)|
|4.||Bombardier, Claire: 2 articles (09/2014 - 01/2014)|
|5.||Seth, Rakhi: 2 articles (09/2014 - 01/2014)|
|6.||Buchbinder, Rachelle: 2 articles (09/2014 - 01/2014)|
|7.||Edwards, Christopher J: 2 articles (09/2014 - 01/2014)|
|8.||Fuldeore, Mahesh J: 2 articles (07/2009 - 02/2009)|
|9.||Mikuls, Ted R: 2 articles (07/2009 - 02/2009)|
|10.||Halpern, Rachel: 2 articles (07/2009 - 02/2009)|
01/30/1982 - "It is concluded that sulphinpyrazone is effective in the prevention of reinfarction in patients surviving a recent myocardial infarction."
01/01/1979 - "Sulfinpyrazone appears to be effective in reducing cardiac deaths during the first year after myocardial infarction."
02/09/1978 - "Sulfinpyrazone appears to be effective in reducing cardiac deaths during the first year after myocardial infarction."
05/01/1987 - "A serial study of platelet reactivity throughout the first six months after myocardial infarction: its modification by sulphinpyrazone."
01/30/1982 - "In a multicentre double-blind randomised study comparing the effects of sulphinpyrazone 400 mg twice daily with those of placebo in patients after myocardial infarction 727 patients (365 on sulphinpyrazone, 362 on placebo) were enrolled and followed up for 12-48 months (mean 19.2). "
09/30/1974 - "Sulfinpyrazone may also be beneficial in preventing thrombosis in arteriovenous canulas. "
04/01/1990 - "The results show that sulphinpyrazone has the potential to reduce the risk of mural thrombosis following endocardial injury."
04/01/1990 - "Sulphinpyrazone reduces endocardial injury and mural thrombosis."
03/01/1984 - "In seven patients studied on sulfinpyrazone, three platelet scans became negative, two became equivocal, and two were unchanged; the presence and size of thrombus was constant by echocardiography in all seven patients. "
07/01/1981 - "Using an intact animal model without microcirculatory thrombosis, we studied the effects of sulfinpyrazone on ischemic myocardium in 58 anesthetized dogs divided into three groups: control untreated (n =24), group 1 (n = 16), treated daily with 300 mg of sulfinpyrazone for 7 days, and group 2 (n = 18), treated daily with 300 mg of sulfinpyrazone for 7 days but omitting treatment on day 8. Although consistent hemodynamic differences were not apparent, the degree of injury determined by ECG mapping was significantly lower in group 1. The incidence of fibrillation was 54% for control and 0% in group 1. Group 2 had a 44% incidence, suggesting a limited duration of action. "
|3.||Venous Thrombosis (Deep-Vein Thrombosis)
01/01/1977 - "Therefore, the protection against deep vein thrombosis afforded by sulfinpyrazone, a drug which can be taken by mouth as well as by injection, was assessed in a prospective study of 119 patients undergoing elective general or urological surgery. "
01/01/1977 - "Sulfinpyrazone in the dose used in this trial was not effective in reducing the incidence of deep vein thrombosis during elective general surgery."
01/01/1977 - "Sulfinpyrazone and postoperative deep vein thrombosis."
09/30/1974 - "In recurrent idiopathic deep vein thrombosis, sulfinpyrazone may be beneficial. "
03/10/1979 - "In patients with recurrent venous thrombosis, sulfinpyrazone treatment is effective in preventing thrombosis."
11/01/1980 - "We investigated the efficacy of Sulfinpyrazone on the reduction and prevention of ventricular arrhythmias and primary ventricular fibrillation, utilizing a standardized experimental canine preparation. "
01/01/1987 - "In anesthetized dogs, the cumulative intravenous administration of 1.0-40.0 mg/kg sulphinpyrazone failed to alter the ventricular excitation threshold, ventricular refractory period and ventricular fibrillation threshold determined during nonobstructed coronary blood flow. "
08/01/1982 - "Sulfinpyrazone attenuated the reduction of the ventricular fibrillation threshold during sympathetic humoral stimulation. "
01/01/1981 - "These findings suggest that heart rate changes alone may account for the observed protective effect of sulphinpyrazone against early ventricular fibrillation during acute experimental myocardial ischaemia."
01/01/1981 - "An increased duration of occlusion without ventricular fibrillation and reduction in epicardial activation delay in the central ischaemic region were observed after intravenous sulphinpyrazone (n = 7). "
|5.||Hypoprothrombinemias (Prothrombin Deficiency)
01/01/1986 - "Concomitant sulfinpyrazone dosing markedly increased hypoprothrombinemia, decreased clearance of (S)-warfarin, and increased clearance of (R)-warfarin. "
01/01/1982 - "Thus, sulfinpyrazone augmented the hypoprothrombinemia of racemic warfarin stereoselectively by reduced metabolic clearance of S-warfarin. "
09/01/1987 - "Sulfinpyrazone treatment did not affect the hypoprothrombinemia produced by phenprocoumon nor did it significantly alter the plasma elimination kinetics of the individual (R)- and (S)-enantiomers. "
01/01/1982 - "R-warfarin with sulfinpyrazone did not significantly change the hypoprothrombinemia but significantly (p less than 0.05) reduced warfarin concentrations. "
01/01/1982 - "S-warfarin with sulfinpyrazone caused a highly significant augmentation of both the hypoprothrombinemia (p less than 0.001) and the plasma warfarin concentrations (p less than 0.001). "
|1.||Aspirin (Acetylsalicylic Acid)
|7.||Uric Acid (Urate)
|8.||Platelet Aggregation Inhibitors (Antiplatelet Drugs)
|1.||Renal Dialysis (Hemodialysis)
|3.||Artificial Heart (Artificial Hearts)
|4.||Hip Replacement Arthroplasty (Total Hip Replacement)